The Europe Gastroparesis Drugs market size is estimated to be worth USD 1.73 billion by 2026 from USD 1.37 billion in 2021, growing at a CAGR of 4.70% during the forecast period. It captures 25% of the global market.
The market for the Gastroparesis drugs market in Europe is majorly driven by an increase in the number of surgeries that lead to postsurgical gastroparesis and the growing number of people with diabetes. Also, the surge in demand for user-friendly drugs is likely to augment the market growth. In addition, the introduction of new drugs in the market for controlling symptoms like nausea is witnessing a significant demand over the forecast period. Furthermore, the availability of reimbursement for in-patient hospital stays in developed countries is expected to drive Europe Gastroparesis Drugs' growth over the forecast period.
On the other hand, the Initiatives taken by the government and non-government organizations in the developed countries and advancing healthcare infrastructure in Germany, UK, France, and Italy are proving lucrative growth opportunities for the market players, expanding the market growth. Moreover, the growing geriatric population is more prone to various diseases such as diabetes; therefore, Y-O-Y growth in the diabetic population in Europe is augmenting the market growth.
Also, increasing healthcare spending among the people and easy access to healthcare services in the region are further projected to uplift the market growth. Furthermore, over the forecast period, the European diabetic gastroparesis treatment market is expected to rise due to an increase in diabetic gastroparesis medicines to reduce symptoms such as nausea and vomiting.
The idiopathic gastroparesis category had the most significant market share, which is likely to continue during the forecast period. It's a type of gastroparesis that happens for no apparent reason. Nausea, vomiting, early satiety, postprandial fullness, and upper abdominal pain are symptoms of this form of gastroparesis, with abdominal pain being one of the most frequent. Dietary changes, prokinetic medicines, antiemetic pharmacological treatment, and symptom modulators can assist with this disease.
However, adverse effects associated with gastroparesis medicines, the time-consuming regulatory procedure for drug approval, and complications in gastroparesis diagnosis are limiting the market's growth. However, non-prescription drugs to control the symptoms restrict diagnosis of stage 1 and stage 2 gastroparesis.
This research report on the Europe Gastroparesis Drugs market has been segmented and sub-segmented into the following categories:
By Drug Class:
By Disease Class:
By End User:
Geographically, the European market is a close second by market share. The UK captured the largest market share in the European market.
Europe held the second most share in the Gastroparesis Drugs Market over the forecast period, and it is likely to witness significant growth throughout the forecast period. Many companies are likely to benefit from the region since Germany and the United Kingdom have a high prevalence of diabetes, which leads to gastroparesis disease, which accounts for a large portion of the market. Market players can profit from initiatives to help with product approvals and labeling claims for diabetic gastroparesis therapies. Moreover, the enormous untapped market potential in emerging countries such as France, the United Kingdom, and Italy and the advancement of novel gastroparesis medicines present lucrative opportunities for market participants.
Over the forecast period, Germany dominated the gastroparesis drugs market. The factors such as an increase in the diabetic population, growth in the geriatric population, and the introduction of novel drugs to control symptoms such as nausea and vomiting propel the market growth.
On the other hand, the UK is likely to account significant share in the gastroparesis drugs market owing to the availability of advanced healthcare services and favorable reimbursement policies, and increasing investment and funding by the government.
Similarly, the countries such as France, Spain, and Italy are projected to contribute to the European regional market growth. The demand for diabetic gastroparesis treatments has increased in the last decade in these countries, which is expected to accelerate the market growth.
KEY MARKET PLAYERS:
A few of the notable companies operating in the European Gastroparesis drugs market profiled in this report are Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.2 Prokinetic Agents
5.1.3 Antiemetic Agents
5.1.4 Botulinum Toxin Injections
5.1.5 Y-o-Y Growth Analysis, By Drug Class
5.1.6 Market Attractiveness Analysis, By Drug Class
5.1.7 Market Share Analysis, By Drug Class
5.2 Disease Type
5.2.2 Diabetic Gastroparesis
5.2.3 Idiopathic Gastroparesis
5.2.4 Post-surgical Gastroparesis
5.2.6 Y-o-Y Growth Analysis, By Disease Type
5.2.7 Market Attractiveness Analysis, By Disease Type
5.2.8 Market Share Analysis, By Disease Type
5.3 End User
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Drug Class
22.214.171.124 By Disease Type
126.96.36.199 By End User
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Drug Class
220.127.116.11 By Disease Type
18.104.22.168 By End User
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Drug Class
188.8.131.52 By Disease Type
184.108.40.206 By End User
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allergan, Plc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)
8.3 AstraZeneca Plc.
8.4 Cadila Pharmaceuticals Ltd.
8.5 ETX Pharma, Inc
8.6 Evoke Pharma
8.7 GlaxoSmithKline Plc.
8.8 Neurogastrx, Inc.
8.9 Valeant Pharmaceuticals International, Inc.
8.10 Theravance Biopharma
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures